Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyAlaska Medicaid Tzield prior auth Policy Update | …
    Ask Trek AI about this page
    CurrentAlaska MedicaidPolicy N/A

    Tzield (teplizumab) prior authorization

    Customize your policy alerts

    Sign up for all Alaska Medicaid policy alerts

    Know when Alaska Medicaid releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Criteria and authorization requirements for Alaska Medicaid coverage of Tzield (teplizumab) to delay onset of Stage 3 type 1 diabetes in patients meeting stage 2 criteria. Applies to providers requesting prior authorization for Alaska Medicaid members.

    Policy Summary
    PayerAlaska Medicaid
    PolicyTzield (teplizumab) prior authorization
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 21, 2022
    Last ReviewJan 21, 2022
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation confirming stage 2 type 1 diabetes (≥2 islet autoantibodies and dysglycemia), body surface area, and pre-initiation CBC and liver enzymes.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    8 yrsminimum patient age
    14 infusionstotal treatment course

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3 monthsauthorization duration
    ≥2required autoantibodies
    Key lab cutoffscritical lab cutoffs

    Coverage Criteria for Tzield (teplizumab-mzwv)

    Initial Therapy

    Covered when ALL of the following are met:

    Tzield initial approval criteria: 1) Patient is 8 years of age or older; AND 2) Patient has a documented diagnosis of stage 2 type 1 diabetes confirmed by: (a) presence of TWO or more of the following pancreatic islet cell antibodies: Islet cell autoantibody (ICA); Insulinoma-associated antigen 2 autoantibody (IA-2A); Insulin autoantibody (IAA); Zinc transporter 8 autoantibody (ZnT8A); Glutamic acid decarboxylase 65 (GAD) autoantibodies; AND (b) dysglycemia on an oral glucose tolerance test (or alternative glycemic test if oral GTT not available); AND 3) Patient has a complete blood count and liver enzyme panel prior to initiation; AND 4) Provider must submit documentation of patient body surface area in m2.

    All listed conditions must be satisfied before approval.

    Tzield is contraindicated during pregnancy and must not be administered within 30 days prior to planned pregnancy.

    Therapy is not approved for members who currently have Stage 3 type 1 diabetes or who have a clinical history consistent with type 2 diabetes; such presentations meet the policy's denial criteria and will result in claim denial.

    Key Definitions

    Stage 2 type 1 diabetes — definition and requirements
    DefinitionPresence of TWO or more pancreatic islet cell autoantibodies (ICA, IA-2A, IAA, ZnT8A, GAD65) plus dysglycemia on an oral glucose tolerance test or alternative glycemic test.
    Age requirementPatient is 8 years of age or older.
    Required documentationProvider must submit results confirming the antibody findings and dysglycemia, plus patient body surface area in m2.

    Billing and Laboratory Criteria

    Billing HCPCS codesHCPCS
    J3490HCPCS - Unclassified drugs
    J3590HCPCS - Unclassified biologics
    C9399HCPCS - Unclassified drugs or biologicals, by report
    Laboratory thresholds that trigger denial
    LymphocytesLess than 1,000 lymphocytes/mcL — denial trigger.
    HemoglobinLess than 10 g/dL — denial trigger.
    PlateletsLess than 150,000 platelets/mcL — denial trigger.
    ALT/ASTGreater than 2× upper limit of normal (ULN) — denial trigger.
    BilirubinGreater than 1.5× ULN — denial trigger.

    Provider Actions, Authorization & Documentation Requirements

    Prior Authorization

    Prior authorization required; limits and billing

    Prior authorization is required for Tzield. Initial approval is limited to 3 months; reauthorization is not approved because the treatment is a single course of 14 daily infusions. Bill using the listed HCPCS codes.

    • Initial Approval: 3 months
    • Reauthorization: not approved — 14 infusions total given once daily for 14 days
    • Billing HCPCS: J3490, J3590, C9399
    Note

    Submit complete prior authorization request before initiation

    Submit a complete prior authorization request that includes the required documentation outlined in policy (diagnosis confirmation, labs, and BSA) before initiating therapy.

    • Ensure CBC and liver enzyme panel are obtained prior to initiation
    • Provide patient body surface area in m2

    Background

    Tzield (teplizumab-mzwv) is a CD3-directed (anti‑CD3) monoclonal antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and pediatric patients aged 8 years and older who have Stage 2 disease. Treatment is given as a 14‑day daily intravenous infusion using body surface area–based dosing.

    Revision History

    2022-01-21policy_effectiveLatest

    Policy effective and last revised on 2022-01-21 establishing prior authorization criteria, duration of approval, coding, and clinical requirements for Tzield (teplizumab).

    Policy Summary
    PayerAlaska Medicaid
    PolicyTzield (teplizumab) prior authorization
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 21, 2022
    Last ReviewJan 21, 2022
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation confirming stage 2 type 1 diabetes (≥2 islet autoantibodies and dysglycemia), body surface area, and pre-initiation CBC and liver enzymes.
    SourceLink
    On This Page
    Coverage Criteria for Tzield (teplizumab-mzwv)Key DefinitionsBilling and Laboratory CriteriaProvider Actions, Authorization & Documentation RequirementsBackgroundRevision History
    Documentation Required

    Required documentation to support PA

    Provider must submit documentation confirming a diagnosis of stage 2 type 1 diabetes, including evidence of ≥2 pancreatic islet autoantibodies and dysglycemia, plus pre-initiation labs and patient BSA.

    • Documentation showing presence of TWO or more islet cell autoantibodies (ICA, IA-2A, IAA, ZnT8A, GAD65)
    • Evidence of dysglycemia on oral glucose tolerance test or alternative glycemic test
    • Pre-initiation complete blood count and liver enzyme panel
    • Patient body surface area (m2)
    Denial Risk

    Denial triggers and exclusion conditions

    Requests will be denied if approval criteria are not met or if exclusion conditions are present; specific laboratory and clinical conditions listed in policy will also trigger denial.

    • Failure to meet approval criteria
    • Patient currently has stage 3 type 1 diabetes
    • Clinical history consistent with type 2 diabetes
    • Active serious or chronic infection (e.g., EBV or CMV)
    • Any of the following lab abnormalities: lymphocytes <1,000/mcL; hemoglobin <10 g/dL; platelets <150,000/mcL; ALT or AST >2×ULN; bilirubin >1.5×ULN